Clinical Trials Logo

Brain Tumor clinical trials

View clinical trials related to Brain Tumor.

Filter by:

NCT ID: NCT04463979 Recruiting - Brain Tumor Clinical Trials

Perioperative Evaluation of Cerebellar Tumors

Start date: February 28, 2021
Phase:
Study type: Observational

This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors.

NCT ID: NCT04427384 Recruiting - Brain Tumor Clinical Trials

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Start date: September 11, 2020
Phase:
Study type: Observational [Patient Registry]

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

NCT ID: NCT04320108 Recruiting - Stroke Clinical Trials

ESWT for Shoulder Pain in Patients With Brain Damage

Start date: May 29, 2020
Phase: N/A
Study type: Interventional

This study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (ESWT) for upper extremity pain related to spasticity in patients with spinal cord injury.

NCT ID: NCT04288505 Recruiting - Brain Tumor Clinical Trials

Evaluation of a Virtual Reality Tool for Identifying the Cognitive Functions of the Right Hemisphere in Patients With Glioma -TANGO

TANGO
Start date: May 28, 2020
Phase: N/A
Study type: Interventional

Evaluate the diagnostic performance of a virtual reality application to detect the presence of cognitive impairment of the non-dominant hemisphere in patients with glioma

NCT ID: NCT04233788 Recruiting - Glioma Clinical Trials

Metabolic Characterization of Space Occupying Lesions of the Brain

FASTMRSI
Start date: September 1, 2021
Phase:
Study type: Observational

High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not. The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas. A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.

NCT ID: NCT04181684 Recruiting - Neoplasms Clinical Trials

LITT Followed by Hypofractionated RT for Recurrent Gliomas

GCCC 19140
Start date: January 8, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.

NCT ID: NCT04180046 Recruiting - Brain Tumor Clinical Trials

Utility of Primary Glioblastoma Cell Lines

Start date: June 26, 2019
Phase:
Study type: Observational

In this study, the characterization of human malignant glioma cell lines is described. After mechanical and enzymatic digestion of glioblastoma human biopsies from Neuromed IRCCS Neurosurgery patients, the investigators analyzed the established cell lines by immunohistochemistry. The investigators have already characterized 10 cell lines and results revealed that not all cell lines are positive for glial fibrillary acidic protein (GFAP), but only one was positive: the so-called COGI cell line. Moreover, the expression of Isocitrate Dehydrogenase 1(IDH1) and alpha thalassemia/mental retardation syndrome X-linked protein (ATRX) was investigated in all established cell lines. COGI cell line was also positive for IDH1R132 mutation and for ATRX. The results of characterization were summarized in table 1.

NCT ID: NCT04178057 Recruiting - Brain Tumor Clinical Trials

Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.

Start date: October 16, 2018
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety and tolerability, pharmacokinetic profiles, immunogenicity of GB222 in Chinese patients with relapsed/progressive high-grade glioma; moreover, changes in cerebral edema, changes in KPS score from baseline, objective response rate (ORR), 4-month progression-free survival (PFS), overall survival (OS)will be evaluated. The dose reduction of hormone during continuous administration period will be observed.

NCT ID: NCT04101123 Recruiting - Cancer Clinical Trials

Children and Adolescents With Leukemia, Brain Tumors, and Sarcomas

SUPATEEN
Start date: January 1, 2020
Phase:
Study type: Observational

Aim of this study is to investigate the influence of social factors on participation and activity among children and adolescents aged 10-18 years with leukemia, brain tumors, and sarcomas. Furthermore personal and treatment-related factors and their impact on participation will be explored

NCT ID: NCT04075305 Recruiting - Breast Cancer Clinical Trials

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

MOMENTUM
Start date: February 1, 2019
Phase:
Study type: Observational [Patient Registry]

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.